Andrew Endy

Associate Chair of Bioengineering & President of BioBricks Foundation


Dr. Andrew (Drew) Endy is associate chair of bioengineering at Stanford University and president of the BioBricks Foundation (biobricks.org). His students invented amplifying genetic logic, rewritable DNA data storage, LEGO-like standard biological parts, genome refactoring, and synthetic genetic codes that resist evolution. Drew helped launch new undergraduate majors in bioengineering at both MIT and Stanford, and also co-founded the iGEM, a genetic engineering “Olympics” that has enabled over 50,000 students globally to learn about and practice biotechnology (igem.org).

His students have gone on to start and lead various companies (e.g., Gingko Bioworks, Octant). Drew has served on DARPA ISAT, chairing DARPA's 2003 Synthetic Biology study, the US National Science Advisory Board for Biosecurity, and the National Academies standing Committee on Science, Technology, & Law. More recently, Drew has served on the World Health Organization's Smallpox Advisory Committee and the International Union for the Conservation of Nature's Synthetic Biology Task Force. Drew was a cofounder of Gen9, Inc., a DNA construction company; he returned as a director while Gen9 was successfully acquired.

Drew worked briefly with the Rapid Evaluation group at Google [X] and on the team that developed the new Shriram building at Stanford. He served as founding co-director of the Departments of Commerce and Energy’s Joint Initiative for Metrology in Biology (jimb.stanford.edu). The White House recognized Drew for his work on open-source biotechnology; the Technische Universiteit Delft awarded him an honorary doctorate; and Esquire declared him one of the 75 most influential people of the 21st century.

He earned degrees in civil and environmental engineering from Lehigh University and a PhD in biochemical engineering from Dartmouth College. He lives on Stanford’s campus with Dr. Christina Smolke (CEO of Antheia), two boys, two cats, and one dog.